Dr. Marina Garassino discusses adjuvant alectinib in resected #ALK NSCLC at #RomeLung24 . Profound benefit and our standard of care even but some questions: what will OS impact be? Should we also give chemotherapy? What impact does variant have? Is 2 years enough?

One of our valuable client's reviews.

Caring for my grandma, a lung cancer patient in the UK, was challenging due to the rarity and cost of prescribed medications.

I Spotted Alecnib on Medicine For World (MFW),

#AntiCancer #Lungcancer #Alectinib #MFW

FDA approves adjuvant alectinib for ALK+ NSCLC, bolstering post-surgery treatment options #oncology #cancer #cancer research #clinicaltrials #OncWeekly buff.ly/4aUPBxU

Alectinib improved disease-free survival compared with chemotherapy in patients with early stage, resected ALK-positive non–small-cell lung cancer. jwat.ch/4b1ji0q

NEJM Jyoti D Patel

.Brendon Stiles giving insightful & thought-provoking discussion on ALINA. DFS survival benefit associated w/ adjuvant alectinib for resected ALK+ stage II-IIIA NSCLC even in pts w/ N0 disease. “will it predict OS?” “Should we give chemo for stage III?” #AATS2024 Montefiore Cardiothoracic Surgery Residency

Stephen V Liu, MD Marina Garassino Real world compliance with full dose adjuvant therapies is much lower than in trials

🇬🇧 adjuvant Osimertinib RWE study found dose reduction rate double that of ADAURA

Suspect we might see similar with adjuvant Alectinib?

Excellent AATS Plenary lecture from Dr. Wu on improved survival with adjuvant alectinib in ALK+ NSCLC in the ALINA trial, and excellent discussion from Brendon Stiles on the pros, cons, and modern challenges of adjuvant targeted therapy #lcsm #AATS2024

This weeks Targeted Top 5 features news on #FDA approvals such as tovorafenib, nogapendekin, alectinib, & more!

1. targetedonc.com/view/fda-grant…
2. targetedonc.com/view/fda-appro…
3. targetedonc.com/view/fda-calls…
4. targetedonc.com/view/establish…
5. targetedonc.com/view/fda-appro…

#FDA approves adjuvant use of #Alectinib (Alecensa) post-tumor resection for tumors ≥4cm or node positive. ALINA trial data shows 76% risk reduction in disease recurrence or death compared to chemo.
Stay updated with #Mellalta at: mellalta.com
#LungCancer #FDA Approval

Lung cancer treatment options are exploding! Targeted agent use in neoadjuvant and adjuvant sphere is a big focus. Does Alectinib work in adjuvant setting and can osimertinib find a role neoadjuvantly? Truly a fascinating time! #lungcancer #MedEd

open.spotify.com/episode/3HrJSI…

Alectinib has been approved by the FDA for use as adjuvant treatment following tumor resection in patients with ALK-positive NSCLC whose tumors are at least 4 cm or node positive. U.S. FDA #lcsm #oncology onclive.com/view/fda-appro…

Recent #FDA approvals such as tovorafenib, nogapendekin, and alectinib, are included in this recap. We also cover boxed warnings for CAR T-cell therapies and analysis advancements for papillary thyroid microcarcinoma.

targetedonc.com/view/targeted-…

La #FDA 🇺🇸 approuve l'adjuvant #Alectinib dans le traitement du CPNPC ALK+

Le 18 avril 2024 également, la FDA a accordé son approbation à l'alectinib comme traitement adjuvant après une résection tumorale pour le traitement des patients atteints d' un CPNPC ALK positif dont les…

Henning Willers, MD Corinne Faivre-Finn 💙 Indeed
A state of mind and, interestingly, “resectability” seems to differ whether being discussed on the podium at a society meeting vs a local tumor board.

Biniam Kidane has nice threads on this.

Separately, is alectinib available there for the ALK+ tumor?

1/ 🚨 Cancer Treatment Update:

The FDA has recently approved alectinib (Alecensa) as the first adjuvant therapy for #LungCancer patients with ALK-positive non-small cell lung cancer post-surgery. A major step forward for high-risk patients. 📄 pcori.me/4ab0RVS

Compensar Supersalud MinSalud Colombia 🇨🇴 Guillermo Jaramillo Gustavo Petro tenemos una situación con el medicamento Alectinib que sirve para el tratamiento de CÁNCER. Llevamos 3 días solicitándolo y nada.El cambio si pero no así, quien responde?

💊 #Medicamentos | Aproximadamente la mitad de los #pacientes con CPNM en estadios iniciales experimentan una recaída de la #enfermedad tras la cirugía

EU Medicines Agency Roche España #cáncer #cáncer depulmón #oncología
i.mtr.cool/ptnuktfrpv

The FDA approved alectinib as an adjuvant treatment for patients with ALK-positive non–small cell lung cancer following tumor resection. #NSCLC #LCSM
targetedonc.com/view/fda-appro…

📺 WATCH D. Ross Camidge, MD, PhD, discuss the recent approval of alectinib in ALK+ NSCLC. #NSCLC #lcsm | D. Ross Camidge

cancernetwork.com/view/alectinib…